Kunming, Sept 4, 2026 — Yunnan’s Government Procurement and Concession Center announced the online listing of selected products for the second round of national coronary stent volume-based procurement, launching a new procurement cycle running from Sept 15, 2026, to June 30, 2029, while terminating transaction eligibility for products under the previous agreement.

Policy Snapshot

Key Provisions

• Selected product listing — Winning products are listed on the procurement subsystem for transaction and settlement. Products listed under the previous agreement period are simultaneously delisted.
• Distributor designation — Selected enterprises independently designate distribution partners through the procurement subsystem and establish delivery relationships. Annual tripartite agreements are signed to define rights and obligations.
• Price governance — Non-selected products with excessively high listed prices are assigned “red/yellow” warning labels. Enterprises receiving targeted notifications must adjust prices accordingly; those without notifications are outside this round’s price governance scope.
• Dynamic listing compliance — Non-selected products must follow the dynamic listing rules under Yunnan Medical Security Bureau [2022] No. 92 for application and price adjustment.
• System registration — Enterprises without existing accounts must complete registration on the procurement subsystem per the March 20, 2024, platform notice.

Market Impact Analysis

The nearly three-year procurement cycle provides supply certainty for coronary stent manufacturers and cardiology departments across Yunnan’s public hospital network. By automatically terminating the previous agreement and activating the new second-round listings, regulators are ensuring a clean transition without overlapping transaction eligibility that could confuse hospital procurement officers.

The “red/yellow” warning system for non-selected products is a particularly consequential market-shaping tool. By flagging overpriced non-winners, the mechanism extends the price compression effect of national volume-based procurement beyond the selected supplier pool, pressuring the entire competitive set to align with national benchmarks or risk exclusion from hospital formularies. This creates a de facto price ceiling for the coronary stent market in Yunnan, compressing margins for both domestic and international manufacturers that failed to secure selected status.

For selected enterprises, the ability to independently designate distributors offers operational flexibility, though the annual tripartite agreement structure introduces yearly renegotiation leverage points for hospitals. The requirement for enterprises without platform accounts to register before participating ensures full traceability in the procurement chain but may delay market entry for smaller manufacturers unfamiliar with Yunnan’s digital procurement infrastructure.

Forward-Looking Statement

Industry analysts expect the Sept 15 launch to serve as a template for other provincial procurement centers rolling out the national coronary stent second-round agreement in the coming weeks. The three-year cycle ending in mid-2029 gives manufacturers long-term volume visibility, though the annual distributor agreement renewals create recurring compliance checkpoints. The red/yellow price warning system is likely to be replicated across other high-value device categories—such as orthopedic implants and pacemakers—as provincial regulators seek to manage non-selected product pricing without resorting to formal delisting. Companies with coronary stent portfolios should monitor Yunnan’s platform closely, as the dynamic listing rules for non-selected products may trigger additional price adjustment mandates before year-end.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27794&CatalogId=3